Â鶹´«Ã½

News — Peripheral nerve injuries are clinical conditions that often result in functional deficits, compromising patient quality of life. Given the relevance of these injuries, new treatment strategies are constantly being investigated. Although mesenchymal stem cells already demonstrate therapeutic potential due to their paracrine action, the transdifferentiation of these cells into Schwann-like cells (SLCs) represents a significant advancement in nerve injury therapy. Recent studies indicate that SLCs can mimic the functions of Schwann cells, with promising results in animal models. However, challenges remain, such as the diversity of transdifferentiation protocols and the scalability of these therapies for clinical applications. A recent study by Zou et al provided a comprehensive overview of the role of bone marrow-derived mesenchymal stem cells in the treatment of peripheral nerve injuries. Therefore, we would like to discuss and explore the use of SLCs derived from bone marrow-derived mesenchymal stem cells in more detail as a promising alternative in the field of nerve regeneration.

Core Tip: Schwann-like cells (SLCs) derived from bone marrow-mesenchymal stem cells have emerged as a promising therapeutic approach for peripheral nerve regeneration. However, further in vitro and in vivo studies are needed to optimize transdifferentiation and transplantation methodologies, as well as to explore the efficacy of SLCs in different injury models. The development of strategies that integrate SLCs could enhance neuroregeneration, promoting cell survival and therapeutic success.

• Citation: Ferreira LVO, Amorim RM. Perspectives on Schwann-like cells derived from bone marrow-mesenchymal stem cells: Advancing peripheral nerve injury therapies. World J Stem Cells 2025; 17(2): 102702
• URL:
• DOI: